Bioheng
Nanjing
About Bioheng
BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $124.5M
- Funding stage: Late Stage Venture
- Last round: Series C (Nov 2024)
- Website: bioheng.com
- Phone: 400-828-8076
Industries & Categories
Biopharma, Biotechnology, Clinical Trials, Health Care, Innovation Management
Canonical: https://fsome.com/organization/bioheng-4386 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.